Now, on the eve of the meeting, the company has announced
that it has orders booked for 500 more complete genome sequences
. The press release also notes that the company successfully churned out a total of 50 sequences in 2009 for more than 10 customers.
These are impressive numbers for a company whose technology and business model – a unique “genome factory” approach in which its technology is deployed only in its own custom-built facilities rather than sold to genome facilities – were regarded with profound skepticism by many researchers in the AGBT audience last year. Will the company be able to meet its stated target of 10,000 genomes
(oops, I mean 5,000 genomes
) this year? We’ll see.
Anyway, I’m looking forward to seeing what else the company has to say in the presentation by its CSO Rade Drmanac
Subscribe to Genetic Future.